Cholinesterase inhibitors (ChEIs) are the first line pharmacotherapy for the symptoms of Alzheimer’s disease (AD). Though ChEIs offer modest cognitive benefits in early AD, literature addressing their continued use in severe AD is scarce. This study assessed the safety of discontinuing ChEIs in institutionalized moderate-severe AD patients. Twenty-six patients were randomized, double-blind to ChEI continuation or placebo for 8-weeks. Vitals, weight (kg) and adverse events (AEs) were monitored biweekly. Chi-square test revealed no significant association between semi-blinded treatment allocation and AE occurrence (χ²=(1,26)=0.99, p=0.32). Groups showed no differences on clinically significant weight loss (χ²=(1,26) =1.9, p=0.17), mean weight loss (F=.531, p= .473), pulse rate (F=.624, p=.437), or side effects (F=.224, p=.640). Preliminary results suggest that either ChEIs are well tolerated or that these drugs are no longer providing therapeutic benefit. Study completion (recruitment of 60 patients and unblinding) will generate more comprehensive data for determination of safe ChEI discontinuation guidelines.

Background: Dementia leads to progressive cognitive and functional decline. Population aging is a concern, and the healthcare system must refocus its limited resources to keep up with service demands. Three cholinesterase inhibitors (ChEIs) – donepezil, galantamine and rivastigmine – have been approved for the treatment of dementia and are covered under Ontario’s formulary plan, but there has been little research regarding their economic impact. Methods: The purpose of this study was to describe the patterns of use of ChEIs, and to assess associated health resource utilization and costs to Ontario’s healthcare system. Anonymized patient-level data from seven provincial administrative databases were linked at the Institute for Clinical and Evaluative Sciences at Queen’s University. First-time users of ChEIs aged 66 years and older were identified between April 1st, 2004 and March 31st, 2009, and were followed until treatment discontinuation or up to one year following their index date. Health resource use was classified into six care categories: prescription drugs, physicians, long-term care, home care nursing, emergency department, and hospitalizations. Chi-square, Kruskal-Wallis ANOVA and linear regression were employed to compare resource use between users of the three ChEIs. Results: In the cohort (N=40,057), the majority were prescribed donepezil (n=24,347), were female (60.5%) and had at least one other co-morbid disease. The odds of discontinuation were 1.47 (1.36, 1.60) and 1.26 (1.17, 136), higher for rivastigmine users than galantamine and donepezil users, respectively. Between 2005 and 2008, overall healthcare costs increased from $95.2 million to $106.1 million. Prescription drugs comprised 33% of all healthcare costs. ChEIs accounted for half of all prescription drug costs. Overall mean annual healthcare system cost per patient was $12,679.47 ($12,510.86, $12,848.08). Predictors of overall healthcare costs included long-term care, co-morbidity status, hospitalization and hip fractures. Conclusions: Prescription drugs account for a substantial proportion of healthcare costs for patients with dementia, and the amount attributable to ChEIs alone is significant. Knowing the health service utilization patterns for dementia patients can help healthcare professionals and decision-makers plan patient care and timely resource allocation. The results stress the utility of administrative databases and the need for further research for this disease. / Thesis (Master, Community Health & Epidemiology) -- Queen's University, 2011-11-01 15:49:58.417

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 5 uppsatser.

Submitted by JULIANA BUENO SANTANA null (juli_bsantana@hotmail.com) on 2016-05-05T15:29:58Z No. of bitstreams: 1 Dissertação final.pdf: 1846480 bytes, checksum: 4a7009afba6cc2b58f17ba4282681092 (MD5) / Approved for entry into archive by Felipe Augusto Arakaki (arakaki@reitoria.unesp.br) on 2016-05-09T13:47:58Z (GMT) No. of bitstreams: 1 santana_jb_me_sjc.pdf: 1846480 bytes, checksum: 4a7009afba6cc2b58f17ba4282681092 (MD5) / Made available in DSpace on 2016-05-09T13:47:58Z (GMT). No. of bitstreams: 1 santana_jb_me_sjc.pdf: 1846480 bytes, checksum: 4a7009afba6cc2b58f17ba4282681092 (MD5) Previous issue date: 2016-02-22 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A doença periodontal (DP) é uma das infecções mais comuns dos seres humanos e é caracterizada pela destruição dos tecidos de suporte dentários, incluindo o osso alveolar. Recentemente tem sido demonstrado que a regulação sistêmica da remodelação óssea é feita também por duas ramificações do Sistema Nervoso Autônomo: a simpática, que favorece a perda óssea, e a parassimpática, que favorece o acréscimo de massa óssea. O objetivo desse trabalho foi verificar, através da administração de inibidores da acetilcolinesterase, o efeito da neuromodulação parassimpática na DP induzida e no tecido ósseo em camundongos. Foram utilizados 40 camundongos machos, divididos em 4 grupos: (1) Grupo Galantamina (G), dez animais com DP induzida e tratados com 3 mg/Kg/dia de Galantamina; (2) Grupo Donepezil (D), dez animais com DP induzida e tratados com 2 mg/Kg/dia de donepezil; (3) Grupo Ligadura (L), dez animais com DP induzida; e (4) Grupo Controle (C). A indução da doença periodontal foi realizada com a inserção de fio de algodão ao redor dos primeiros molares inferiores e o tratamento durou 42 dias. No dia do sacrifício, amostras de sangue foram coletadas para análise sorológica do fator nuclear κB ligante (RANKL) e osteoprotegerina (OPG). As hemimandíbulas esquerdas foram submetidas à análise histomorfométrica e os fêmures esquerdos, ao teste de flexão em três pontos para avaliação das propriedades extrínsecas e intrínsecas. O uso dos medicamentos não reduziu a perda óssea alveolar dos grupos tratados. Também não foram observadas diferenças estatísticas significantes com relação às propriedades biomecânicas dos fêmures ou à concentração sérica de RANKL e OPG. Concluímos que a galantamina e o donepezil, nas doses e período utilizados, não influenciaram a patogênese da DP ou a remodelação óssea sistêmica. / Periodontal disease (PD) is one of the most common infections of human beings, and it is characterized by destruction of tooth supporting tissues, including alveolar bone. Recently it has been shown that the systemic regulation of bone remodeling is also made by two branches of the autonomic nervous system: the sympathetic, favoring bone loss and the parasympathetic, which promotes increase of bone mass. The aim of this study was to verify, through the administration of acetylcholinesterase inhibitors, the effect of parasympathetic neuromodulation in induced periodontitis and bone tissue in mice. Forty male mice were divided into 4 groups: (1) Group Galantamine (G), ten animals with induced PD and treated with 3 mg/ kg/day of galantamine; (2) Donepezil group (D), ten animals with induced PD and treated with 2 mg/kg/day of donepezil; (3) Ligature group (L), ten animals with induced PD; and (4) control group (C). The induction of periodontal disease was carried out with a cotton thread insertion around the lower first molars and the treatment lasted 42 days. On the day of sacrifice, animalsblood samples were collected for serological analysis of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG). The left hemimandibles were submitted to histomorphometric analysis and the left femur to the three point bending test for assessment of extrinsic and intrinsic properties. The use of the drugs did not reduce alveolar bone loss in treated groups. No statistically significant differences regarding the biomechanical properties of femurs or serum RANKL and OPG were observed. We conclude that galantamine and donepezil, at doses and time used, did not influence the pathogenesis of PD or systemic bone remodeling. / CNPq: 459759/2014-0

Orientador: Roberto Rittner Neto / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-21T10:40:13Z (GMT). No. of bitstreams: 1 Bitencourt_Michelle_M.pdf: 771721 bytes, checksum: 1771939b9c0680c7375ae9953fca996f (MD5) Previous issue date: 2012 / Resumo: O presente trabalho trata de um estudo sobre compostos que se comportam como inibidores da acetilcolinesterase, uma importante enzima do processo de cognição. A acetilcolinesterase atua na hidrólise da acetilcolina, responsável pela comunicação entre os neurônios. Uma das modalidades para o design racional de fármacos é a estimativa de propriedades biológicas de novas moléculas utilizando métodos computacionais. Análise quantitativa entre estrutura química e atividade biológica (QSAR) é uma dessas técnicas. No presente trabalho, análise multivariada de imagens aplicada em QSAR (MIA-QSAR) foi utilizada para se construírem modelos QSAR preditivos para uma série congênere de carbamatos com atividade anticolinesterásica. Os bons resultados estatísticos da modelagem credenciaram o modelo MIA-QSAR construído a predizer a atividade biológica de alguns novos derivados, potencialmente úteis para o tratamento do Mal de Alzheimer / Abstract: The present work describes the study of some compounds which act as acetylcholinesterase inhibitors a very important enzyme in the cognitive process. zAcetylcholinesterase is responsible by the hydrolysis of acetylcholine, which accounts for the communication among the neurons. One of the approaches for the rational pharmaceuticals design is the estimation of the biological properties of new molecules using computational methods. The quantitative analysis between chemical structure and biological activity (QSAR) is one of these techniques. In the present work, the multivariate analysis of images applied in QSAR (MIA-QSAR) was employed for building predictable QSAR models for a congenial series of carbamates which exhibit anticholinesterase activity. The significant statistical results from this treatment enabled the MIA-QSAR model thus obtained to reliably predict the biological activity of some new derivatives, as potentially useful for the Alzheimer Disease treatment / Mestrado / Ciencias Biomedicas / Mestra em Ciências Médicas

Orientador: / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-18T16:30:22Z (GMT). No. of bitstreams: 1 Pinheiro_GlauciaMelinaSquizato_M.pdf: 10487701 bytes, checksum: fedb6a8be09bd0cb49b2fe1aaca9ba90 (MD5) Previous issue date: 2011 / Resumo: Este trabalho descreve um estudo teórico-experimental envolvendo derivados da Piridostigmina e do Edrofônio, que possuem ação como inibidores da enzima acetilcolinesterase. Os anticolinesterásicos são utilizados como medicamento para o tratamento do Mal de Alzheimer. Primeiramente foram sintetizados os derivados da Piridostigmina (brometo de N,N-dimetilcarbamato de N'-metilpiridínio), com substituintes no carbono 5 do anel piridínico: fenila, p-metoxifenila, p-nitrofenila, p-clorofenila, e um derivado do Edrofônio (brometo de 2,6-tetraidro-N,N-dimetil-3-hidroxi-5-fenilpiridínio). O procedimento proposto envolveu como intermediários os 2,6-tetraidro-N,N-dimetil-3-oxo-5-fenilpiridínio p-substituídos, com estrutura de sal interno (cargas negativa e positiva no oxigênio e nitrogênio, respectivamente). Todos os compostos tiveram suas propriedades físico-químicas (ponto de fusão, análise elementar) e espectroscópicas (RMN e IV) analisadas, tanto para os sais cíclicos intermediários como para os produtos finais. Através de cálculos teóricos analisamos as geometrias moleculares e densidades de carga dos compostos finais. Investigamos também as propriedades biológicas referentes à atividade anticolinesterásica do derivado do Edrofônio determinada através do Método de Ellman modificado. Neste teste observamos que este composto possui uma atividade anticolinesterásica superior ao fármaco comercial, sendo que, o fármaco comercial inibiu 62,9% a atividade enzimática total, contra 100% de inibição do composto, ambos na concentração de 0,1 mol / L / Abstract: This project describes a theoretical and experimental study involving pyridostigmine and edrophonium derivatives, which can be used as inhibitors of the acetylcholinesterase enzyme. The anticholinesterase agents are used as medicine for the treatment of Alzheimer's disease. Firstly pyridostigmine (N,N-dimethylcarbamate N'-methyl-5-phenyl-pyridinium bromides) derivatives (phenyl, p-nitrophenyl, p-chlorophenyl, p-methoxyphenyl) and 2,6-tetrahydro-N,N-dimethyl-3-hidroxy-5-phenylpyridine bromide (edrophonium derivative) were prepared. All compounds were characterized from their physicochemical (melting point, elemental analysis) and a spectroscopic property (NMR and IR) for both cyclic salts intermediates and the final products. Through theoretical calculations it has been assessed molecular geometries and charge densities of the final compounds. It has also been investigated the biological properties related to the activity of anticholinesterase edrophonium derivative, which was accessed from modified Ellman method. It has been found that edrophonium derivative present anticholinesterase activity much higher than the commercially available drug. From our results, while commercial drug inhibit 62.9% of the total enzyme activity, edrophonium derivative inhibit 100%, both at the same concentration (0.1 mol L-1) / Mestrado / Ciencias Biomedicas / Mestre em Ciências Médicas

A doença de Alzheimer (DA) é uma doença neurodegenerativa e a principal causa de demência em idosos. Os mecanismos fisiopatológicos mais envolvidos na DA são: o acúmulo do peptídeo beta amiloide (A?) em agregados extracelulares, e a formação dos emaranhados neurofibrilares (ENF). A Proteína Precursora do Amiloide (APP) é clivada pelas secretases alfa (ADAM10), beta (BACE1) e y (Presenilina 1 [PSEN1]). As plaquetas contêm 95% da APP circulante e possuem toda a maquinaria necessária para estudar perifericamente a APP e suas secretases. A pesquisa de biomarcadores na DA tem como objetivo identificar, em vida, os indicadores do processo patogênico em fluídos corporais e/ou por métodos de imagem cerebral. O objetivo do presente estudo foi investigar proteínas envolvidas no metabolismo da APP em plaquetas de pacientes com DA e o potencial de modificação destas vias pela ação do tratamento com cloridrato de donepezila. Para tanto foram analisadas amostras de 23 pacientes com DA leve ou moderada, avaliados antes e depois de 6 meses de tratamento e 38 indivíduos idosos cognitivamente saudáveis (controles). As variáveis de desfecho estudadas foram: (1) expressão protéica de ADAM10, BACE1 e PSEN1; (2) expressão protéica dos metabólitos secretados da APP de 110 e 130kDa, possibilitando o cálculo da razão de APP (rAPP); e (3) atividade enzimática das APP-secretases ADAM10 e BACE1. Foram utilizados os métodos de western blotting e o fluorimétrico. Encontramos, nos pacientes com DA pré-tratamento, uma diminuição da rAPP em relação aos controles; porém, não identificamos diferenças após seis meses de tratamento. Os níveis de ADAM10 mostraram-se menores em pacientes com DA na avaliação basal quando comparados aos controles, mas também sem modificação com o tratamento, o tratamento mostrou-se associado a uma redução da expressão de BACE1 em pacientes com DA, embora não tenhamos encontrado diferenças entre pacientes e controles na avaliação basal. A expressão de PSEN1 mostrou-se menor nos pacientes com DA pré-tratamento quando comparada aos controles, sem contudo haver alteração em resposta ao tratamento. Quanto à atividade enzimática de ADAM10 e BACE1, não observamos diferenças nos valores pré e pós-tratamento. Nossos achados reforçam a utilidade da utilização de plaquetas como matriz biológica para o estudo do metabolismo da APP em tecidos periféricos e para a investigação de efeitos modificadores da patogenia da DA a partir do tratamento com drogas antidemência / Alzheimer\'s disease (AD) is a neurodegenerative disease and the major cause of dementia in the elderly. The main mechanisms in AD are: extracellular aggregates of beta amyloid peptide (Abeta) and neurofibrillary tangles formation (NFT). Amyloid Precursor Protein (APP) is cleaved by the secretases alfa (ADAM10), beta (BACE1) and ? (Presenilin 1 [PSEN1]). Platelets containing 95% of the circulating APP and possess all the machinery necessary to study peripherically APP and its secretases. The search for biomarkers in AD aims to identify, in life, the pathogenic process indicators in body fluids and/or brain image methods. The aim of this study was to investigate proteins involved in APP metabolism in platelets of AD patients, and the potential modification of these pathways by treatment with Donepezil hydrochloride. Therefore, 23 patients with mild to moderate AD evaluated before and after 6 months treatment and 38 healthy elderly subjects (controls) were analyzed. Outcome variables were: (1) ADAM10, BACE1 and PSEN1 expression; (2) APP secreted metabolites expression (110 and 130kDa), allowing the APP ratio (rAPP) estimate; (3) APP-secretase ADAM10 and BACE1 enzymatic activity. Western blotting and fluorimetric methods were used. We found in AD patients pre-treatment, a decrease of rAPP compared to controls; however, we did not identify differences of this parameter after six months of treatment. The ADAM10 levels were lower in AD patients at baseline when compared to controls, however no differences were observed after treatment. Treatment was associated with a reduction of BACE1 expression in AD patients, although we have not found differences between patients and controls at baseline. PSEN1 expression was lower in pre-treatment AD patients compared to controls. No differences were observed after treatment. Concerning to BACE1 and ADAM10 enzymatic activity, we did not observe differences in pre and post-treatment. Our findings strengthen the use of platelets as a biological matrix for the APP metabolism as well as the modifying effects on AD pathogenicity of antidementia drugs

A doença de Alzheimer (DA) é uma doença neurodegenerativa e a principal causa de demência em idosos. Os mecanismos fisiopatológicos mais envolvidos na DA são: o acúmulo do peptídeo beta amiloide (A?) em agregados extracelulares, e a formação dos emaranhados neurofibrilares (ENF). A Proteína Precursora do Amiloide (APP) é clivada pelas secretases alfa (ADAM10), beta (BACE1) e y (Presenilina 1 [PSEN1]). As plaquetas contêm 95% da APP circulante e possuem toda a maquinaria necessária para estudar perifericamente a APP e suas secretases. A pesquisa de biomarcadores na DA tem como objetivo identificar, em vida, os indicadores do processo patogênico em fluídos corporais e/ou por métodos de imagem cerebral. O objetivo do presente estudo foi investigar proteínas envolvidas no metabolismo da APP em plaquetas de pacientes com DA e o potencial de modificação destas vias pela ação do tratamento com cloridrato de donepezila. Para tanto foram analisadas amostras de 23 pacientes com DA leve ou moderada, avaliados antes e depois de 6 meses de tratamento e 38 indivíduos idosos cognitivamente saudáveis (controles). As variáveis de desfecho estudadas foram: (1) expressão protéica de ADAM10, BACE1 e PSEN1; (2) expressão protéica dos metabólitos secretados da APP de 110 e 130kDa, possibilitando o cálculo da razão de APP (rAPP); e (3) atividade enzimática das APP-secretases ADAM10 e BACE1. Foram utilizados os métodos de western blotting e o fluorimétrico. Encontramos, nos pacientes com DA pré-tratamento, uma diminuição da rAPP em relação aos controles; porém, não identificamos diferenças após seis meses de tratamento. Os níveis de ADAM10 mostraram-se menores em pacientes com DA na avaliação basal quando comparados aos controles, mas também sem modificação com o tratamento, o tratamento mostrou-se associado a uma redução da expressão de BACE1 em pacientes com DA, embora não tenhamos encontrado diferenças entre pacientes e controles na avaliação basal. A expressão de PSEN1 mostrou-se menor nos pacientes com DA pré-tratamento quando comparada aos controles, sem contudo haver alteração em resposta ao tratamento. Quanto à atividade enzimática de ADAM10 e BACE1, não observamos diferenças nos valores pré e pós-tratamento. Nossos achados reforçam a utilidade da utilização de plaquetas como matriz biológica para o estudo do metabolismo da APP em tecidos periféricos e para a investigação de efeitos modificadores da patogenia da DA a partir do tratamento com drogas antidemência / Alzheimer\'s disease (AD) is a neurodegenerative disease and the major cause of dementia in the elderly. The main mechanisms in AD are: extracellular aggregates of beta amyloid peptide (Abeta) and neurofibrillary tangles formation (NFT). Amyloid Precursor Protein (APP) is cleaved by the secretases alfa (ADAM10), beta (BACE1) and ? (Presenilin 1 [PSEN1]). Platelets containing 95% of the circulating APP and possess all the machinery necessary to study peripherically APP and its secretases. The search for biomarkers in AD aims to identify, in life, the pathogenic process indicators in body fluids and/or brain image methods. The aim of this study was to investigate proteins involved in APP metabolism in platelets of AD patients, and the potential modification of these pathways by treatment with Donepezil hydrochloride. Therefore, 23 patients with mild to moderate AD evaluated before and after 6 months treatment and 38 healthy elderly subjects (controls) were analyzed. Outcome variables were: (1) ADAM10, BACE1 and PSEN1 expression; (2) APP secreted metabolites expression (110 and 130kDa), allowing the APP ratio (rAPP) estimate; (3) APP-secretase ADAM10 and BACE1 enzymatic activity. Western blotting and fluorimetric methods were used. We found in AD patients pre-treatment, a decrease of rAPP compared to controls; however, we did not identify differences of this parameter after six months of treatment. The ADAM10 levels were lower in AD patients at baseline when compared to controls, however no differences were observed after treatment. Treatment was associated with a reduction of BACE1 expression in AD patients, although we have not found differences between patients and controls at baseline. PSEN1 expression was lower in pre-treatment AD patients compared to controls. No differences were observed after treatment. Concerning to BACE1 and ADAM10 enzymatic activity, we did not observe differences in pre and post-treatment. Our findings strengthen the use of platelets as a biological matrix for the APP metabolism as well as the modifying effects on AD pathogenicity of antidementia drugs

Since neuroinflammation is present in patients with mild cognitive impairment (MCI) andAlzheimer's disease (AD) and since cholinesterase inhibitors increases the level ofacetylcholine, the aim was to investigate whether inflammatory markers of cholinoceptive cellsare affected in these patients. Near a biological hallmark of AD, amyloid plaque, activatedastrocytes and microglia can be found and higher levels of proinflammatory cytokines, i.e. IL-1β. To study the inflammatory response, proteins GFAP and S100B are used as CSF glialmarkers. IL-1β can bind to the membrane-bound IL-1 receptor or soluble sIL-1β-RII. When IL-1β binds to the soluble receptor instead of the membrane-bound receptor, no intracellular signalpropagation occur, thereby sIL-1βRII exerts an antagonistic effect and diminishedinflammatory responses. Thus a reduction in ratio of IL-1β to sIL-1RII levels may be indicativeof anti-inflammatory response. Available data on CSF GFAP, S100B, IL-1β and sIL-1β-RIIlevels in AD patients and MCI patients was used. MCI group were longitudinally followedafter start of treatment with a cholinesterase inhibitor (ChEI). AD group had data from baselineand after short-term treatment with a ChEI. The statistics application StatView was used toanalyse data. The activity of the cholinesterase enzymes, BuChE and AChE showed significantinhibition in the CSF of the MCI patients compared to baseline CSF GFAP level wassignificantly lower in MCI than AD patients at baseline. The levels of both GFAP and S100Bwere increased with time in MCI patients to comparable levels in the AD patients, indicative ofastroglial activation in MCI patients. However, the ratio of IL-1β to sIL-1RII showed alongitudinal reduction in the MCI patients after the treatment with the ChEIso that this ratiowas significantly higher in AD than in MCI patients. Thus despite the activation of astroglialcells in the treated MCI patients the proinflammatory effect of IL-1β was prevented byinduction of sIL-1βRII levels indicative of an anti-inflammatory outcome of treatment. Thisstudy suggests that proper activation of astroglial cells may have beneficial effect on ADpathogenesis, and conversion of MCI to AD. It also suggests that cholinesterase inhibitors may have an anti-inflammatory effect.

Submitted by Iatã do Carmo Mendonça null (iata.mendonca@hotmail.com) on 2018-11-13T19:26:17Z No. of bitstreams: 1 Dissertação Iatã Final.pdf: 6444130 bytes, checksum: 11f109faa73fa111dd02175f3cf51eaf (MD5) / Approved for entry into archive by Ana Carolina Gonçalves Bet null (abet@iq.unesp.br) on 2018-11-21T12:18:13Z (GMT) No. of bitstreams: 1 mendonca_ic_me_araiq_int.pdf: 6335142 bytes, checksum: 3275b085559a59aa0ff58a993812c371 (MD5) / Made available in DSpace on 2018-11-21T12:18:13Z (GMT). No. of bitstreams: 1 mendonca_ic_me_araiq_int.pdf: 6335142 bytes, checksum: 3275b085559a59aa0ff58a993812c371 (MD5) Previous issue date: 2018-10-05 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Considerando a variedade de compostos encontrados em produtos de origem natural, o estudo da biodiversidade de um país é de interesse tanto científico quanto econômico. Sendo possível destacar os ecossistemas marinhos que apresentam biodiversidade comparável às florestas tropicais. Devido ao ambiente diferenciado, muitas vezes inóspito, os habitantes do ambiente marinho exibem características bioquímicas diferenciadas, mostrando grande potencial para bioprospecção. A importância do estudo de organismos marinhos na busca por metabólitos secundários bioativos levou à proposta de aprofundar a prospecção química do fungo endofítico Humicola fuscoatra, isolado da alga vermelha Asparagopsis taxiformis. A partir de seu extrato foi possível purificar por técnicas cromatográficas, e identificar 7 substâncias com base nos dados de ressonância magnética nuclear uni e bidimensional (RMN de 1H, RMN de 13C, TOCSY-1D, COSY, HSQC, HMBC) e espectrometria de massas (EM). Dentre estes foram identificados um composto da classe das dicetopiperazinas (P01), duas isocumarinas (P02 e P05), além de 4 substâncias não relatadas na literatura, incluindo três valerolactamas (P03, P06 e P07) e uma cicloexadienona (P04). Além dos compostos purificados por CLAE, foi possível identificar duas substâncias por cromatografia a gás acoplada a espectrometria de massas (CG-EM) sendo elas uma dicetopiperazina e um ftalato. A variedade estrutural dos compostos isolados e a grande quimiodiversidade do extrato de Humicola fuscoatra reforçam a necessidade de se realizar estudos químicos de fungos endofíticos de origem marinha, visto que estes são uma fonte de metabólitos com grande potencial para contribuir na busca por protótipos para novos agentes terapêuticos, além de enfatizar a importância da preservação dos biomas aquáticos, sob constante ameaça por impactos ambientais e mudanças climáticas. / Seeing the variety of compounds obtained from natural products, study a country biodiversity have a scientific interest as well as economic. It is possible to highlight marine ecosystems that present biodiversity comparable to rainforests. Due to the unique environment, often inhospitable, the organisms of the marine environments display uncommon biochemical characteristics, showing great potential for bioprospecting. The importance of the study of marine organisms in the search for bioactive compounds led to the proposal to deepen the prospection of the endophytic fungus Humicola fuscoatra, isolated from the red alga Asparagopsis taxiformis. Its extract led to the purification by chromatographic methods, and identification of 7 compounds based on their NMR spectral data obtained by uni and bidimensional experiments (1H NMR, 13C NMR, TOCSY-1D, COSY, HSQC, HMBC) and mass spectrometry (MS). One diketopiperazine (P01), two isocoumarins (P02 and P05) in addition to four novel compounds, including three valerolactams (P03, P06 and P07) and one cyclehexadienone (P04) were isolated. Moreover another diketopiperazine and one phthalate derivative were identified by gas chromatography coupled to mass spectrometry (GC-MS). The structural variety of the identified compounds associated to the rich chemodiversity observed for the Humicola fuscoatra extract reinforces the need to develop additional chemical studies of endophytic fungal strains of marine origin, since they have been providing metabolites with great potential to the development of novel therapeutic agents, in addition to emphasize the importance of aquatic biomes preservation, as they have been continuously threatened by environmental and climate change impacts.